eligibility checklist

Funds Available

View the full list of funds available

Read more
eligibility checklist

What type of finance do I need?

Our online eligibility checklist helps you see which type of finance might be right for your business.

Read more
08 April 2014

Anti-stretch mark technology receives £400,500 funding

Press Release 16th April 2014

A BUSINESS which has developed a revolutionary product to help prevent stretch marks during pregnancy has received £400,500 in equity funding from The North West Fund for
Biomedical, managed by SPARK Impact.

The North West Fund for Biomedical is a sub-fund of The North West Fund, a substantial pot of money jointly financed by the European Regional Development Fund and the European Investment Bank and available to invest in small and medium sized businesses in the North West of England to support their start-up, development and growth.

Stuff of Life, which will be moving to Merseyside and creating ten jobs over the next two years, has developed 'Liforma', the first clinically proven preventative product to reduce
the incidence of stretch marks during pregnancy which affects 70 to 90 per cent of pregnant women globally.

The Liforma 'Total Stretch Mark Support' system includes three products - 'The Stretch Mark Support band' which is worn during the day over the pregnancy bump, a day gel
and a night cream. The support band uses a revolutionary technology called 'vector
alignment' which holds skin in place so stretch marks are unable to form.

The funding will be used to finalise and safeguard patents, complete regulatory work, appoint fulfilment partners and create and implement an online and social media strategy for the launch to women who are 12-16 weeks pregnant and healthcare professionals.

Sophie Hooper, chief executive officer at Liforma said: "We are delighted that SPARK Impact has invested in Liforma. They share the company's belief that the product will be a 'must have' for every woman who is pregnant and is concerned about getting stretch marks, and fully support our go-to-market strategies in the UK and the US."

Dr Penny Attridge, investment director at SPARK Impact said: "The Liforma team has worked extremely hard to come up with a unique and clinically proven healthcare product to combat the global problem of stretch marks during pregnancy.

"The investment will provide the boost they need to thrive and we wish them every success in rolling out the commercialisation of the product."

Liforma is the 47th investment for The North West Fund for Biomedical to date.

 

 


Back to article list